Cover of: Antiandrogens in prostate cancer | Read Online
Share

Antiandrogens in prostate cancer a key to tailored endocrine treatment by

  • 148 Want to read
  • ·
  • 79 Currently reading

Published by Springer in Berlin, New York .
Written in English

Subjects:

  • Antiandrogens -- Therapeutic use.,
  • Prostate -- Cancer -- Chemotherapy.

Book details:

Edition Notes

Includes bibliographical references.

StatementL. Denis, (ed.).
SeriesESO monographs, Monographs (European School of Oncology)
ContributionsDenis, L.
Classifications
LC ClassificationsRC280.P7 A58 1996
The Physical Object
Pagination120 p. :
Number of Pages120
ID Numbers
Open LibraryOL20390619M
ISBN 103540605991

Download Antiandrogens in prostate cancer

PDF EPUB FB2 MOBI RTF

Antiandrogens competitively inhibit ligand binding to the androgen receptor (AR), and are used therapeutically in prostate cancer patients. The AR functions as a ligand dependent transcription factor that transduces androgen binding into increased transcription of androgen dependent ://   Review – Prostate Cancer Antiandrogens in the Treatment of Prostate Cancer Manfred P. Wirth*, Oliver W. Hakenberg, Michael Froehner Department of Urology, University Hospital ‘‘Carl Gustav Carus’’, Technical University of Dresden, Fetscherstra D Dresden, Germany 1. Introduction Since the discovery of the beneficial effect of /pdf/antiandrogens-in-the-treatment-of-prostate-cancer.   Title: Antiandrogens in Prostate Cancer Endocrine Therapy VOLUME: 4 ISSUE: 5 Author(s):Z. Culig, G. Bartsch and A. Bartsch Affiliation:Department of Urology, University of Innsbruck, Anichstra A Innsbruck, Austria. Keywords:Antiandrogens, luteinizing hormone releasing hormone (LHRH), nonsteroidal, corepressors, proteins Abstract: Prostate cancer is the most   Results. One steroidal and three non-steroidal antiandrogens are in common use for the treatment of prostate cancer. Monotherapy with non-steroidal antiandrogens may prevent osteoporosis, loss of musculature and may preserve sexual activity in a proportion of patients and therefore has advantages in quality of life compared to ://

RESULTS: One steroidal and three non-steroidal antiandrogens are in common use for the treatment of prostate cancer. Monotherapy with non-steroidal antiandrogens may prevent osteoporosis, loss of musculature and may preserve sexual activity in a proportion of patients and therefore has advantages in quality of life compared to :// Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Introduction. Prostate cancer is an androgen dependent malignancy, first demonstrated in by the Nobel Prize-winning research of Huggins and Hodges showing that reducing serum androgen levels by orchiectomy or exogenous estrogen administration induced tumor regressions and palliation of symptoms (Figure 1).Subsequently gonadotropin-releasing hormone (GnRH) analogs and antiandrogens were Prostate cancer (PCa) is the most common cancer and the 2nd leading cause of cancer-related deaths among men in the United States. Androgen-deprivation-therapy (ADT) with antiandrogens to target the androgens/androgen receptor (AR) signals remains the standard therapy for

  Prostate Cancer Foundation: "Understanding Prostate Cancer--Treatment Options." Reviewed by Carol DerSarkissian on J From: Treatment for Advanced Prostate Cancer Introduction. Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer related deaths among men in the United States [].According to an estimate by the American Cancer Society, approximately , new cases of prostate cancer will be diagnosed deaths will occur from this disease in [].The majority of deaths from prostate cancer is Tobias Gramann, Hans-Peter Schmid, First-Line Hormonal Manipulation: Surgical and Medical Castration with LHRH Agonists and Antagonists, Steroids, and Pure Antiandrogens, Management of Prostate Cancer, /, (), (). Although hormone therapy with antiandrogens has been widely used for the treatment of prostate cancer, some antiandrogens may act as androgen receptor (AR) agonists that may result in antiandrogen withdrawal syndrome. The molecular mechanism of this agonist response, however, remains unclear. Using mammalian two-hybrid assay, we report that antiandrogens, hydroxyflutamide, bicalutamide